Unlock STING polymorphism with a comprehensive HTRF binding platform
STING protein is a mediator of innate immunity and a candidate for auto immune disease or cancer immunotherapy. Clinical trials are already ongoing, and targeting all STING variants has become crucial. R232 is the most common variant, and HAQ and H232 alleles are also present in the human population.
To help you identify and characterize universal new STING therapeutics, Revvity has developed this note with:
How HTRF human and mouse STING assays are built up,
What their main features are,
How the most relevant and promising STING agonists, like ADU-S100, behave towards the different STING variants.
Download your note
We are committed to your privacy. Revvity needs the contact information you provide us to keep you aware about relevant content, products, and services. You may unsubscribe from these communications at any time. For more information check out our Privacy Policy.
